SEC Form 3 · accession 0001209191-18-027478
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stan Blackburn
Other
Period of report
Mar 20, 2018
Accepted (ET)
May 2, 2018 · 8:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 11,954 | I | By the J. Stanhope and Karlene S. Blackburn Family Trust U.T.D. May 2001 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F3 | $0.72 | holding | — | — | — | — | Jun 2, 2021 | Common Stock | 129 | — | D |
| Stock Option (right to buy)F2,F3 | $0.88 | holding | — | — | — | — | Sep 13, 2022 | Common Stock | 878 | — | D |
| Stock Option (right to buy)F2,F3 | $4.06 | holding | — | — | — | — | Sep 26, 2023 | Common Stock | 2,514 | — | D |
| Stock Option (right to buy)F2,F3 | $4.06 | holding | — | — | — | — | Mar 5, 2024 | Common Stock | 1,760 | — | D |
| Stock Option (right to buy)F2,F4 | $9.15 | holding | — | — | — | — | Apr 17, 2025 | Common Stock | 3,143 | — | D |
| Stock Option (right to buy)F2,F5 | $14.00 | holding | — | — | — | — | May 6, 2025 | Common Stock | 4,085 | — | D |
| Stock Option (right to buy)F2,F6 | $10.24 | holding | — | — | — | — | Oct 1, 2025 | Common Stock | 9,500 | — | D |
| Stock Option (right to buy)F2,F7 | $6.14 | holding | — | — | — | — | Jan 27, 2026 | Common Stock | 4,250 | — | D |
Explanation of responses
- F1The Reporting Person is a co-trustee of the J. Stanhope and Karlene S. Blackburn Family Trust U.T.D. May 9, 2001.
- F2All options reported on this Form 3 were granted prior to February 2016 when the Reporting Person was a consultant, serving as the Company's Acting Chief Financial Officer. On March 20, 2018, the Reporting Person became the Company's Principal Financial and Accounting Officer.
- F3This option was fully vested and exercisable at the reporting date.
- F4The shares subject to this option vest in 48 equal monthly installments starting on May 17, 2015 and will be fully exercisable on April 17, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
- F5The shares subject to this option vest in 48 equal monthly installments starting on June 6, 2015 and will be fully exercisable on May 6, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
- F6The shares subject to this option vest in 48 equal monthly installments starting on November 1, 2015 and will be fully exercisable on October 1, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
- F7The shares subject to this option vest in 48 equal monthly installments starting on February 1, 2016 and will be fully exercisable on January 1, 2020. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
Remarks
Principal Financial and Accounting Officer